Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Meropenem × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2 Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Docetaxel 29 Radiosurgery 20 Sunitinib 18 Radiotherapy 18 Gemcitabine 15 Androgen Antagonists 15 Cisplatin 14 Blood Specimen Collection 14 pembrolizumab 13 Nivolumab 13 enzalutamide 11 Leuprolide 11 Surveys and Questionnaires 10 bicalutamide 9 aldesleukin 9 Prednisone 9 Goserelin 9 Cyclophosphamide 9 Carboplatin 9 Bevacizumab 8 tislelizumab 7 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 7 Radiotherapy, Intensity-Modulated 7 Multiparametric Magnetic Resonance Imaging 7 Chemotherapy, Adjuvant 7 Abiraterone Acetate 7 toripalimab 6 pazopanib 6 atezolizumab 6 Triptorelin Pamoate 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05392634 2022-05-31

MACS

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Unknown

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡